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Abstract: We previously hypothesized that increased capillary permeability observed in 
both  hantavirus  cardiopulmonary  syndrome  (HCPS)  and  hemorrhagic  fever  with  renal 
syndrome  (HFRS)  may  be  caused  by  hantavirus-specific  cytotoxic  T  cells  attacking 
endothelial cells presenting viral antigens on their surface based on clinical observations 
and  in  vitro  experiments.  In  HCPS,  hantavirus-specific  T  cell  responses  positively 
correlated  with  disease  severity.  In  HFRS,  in  one  report,  contrary  to  HCPS,  T  cell 
responses negatively correlated with disease severity, but in another report the number of 
regulatory T cells, which are thought to suppress T cell responses, negatively correlated 
with disease severity. In rat experiments, in which hantavirus causes persistent infection, 
depletion  of  regulatory  T  cells  helped  infected  rats  clear  virus  without  inducing 
immunopathology. These seemingly contradictory findings may suggest delicate balance in 
T cell responses between protection and immunopathogenesis. Both too strong and too 
weak T cell responses may lead to severe disease. It is important to clarify the role of T 
cells  in  these  diseases  for  better  treatment  (whether  to  suppress  T  cell  functions)  and 
protection  (vaccine  design)  which  may  need  to  take  into  account  viral  factors  and  the 
influence of HLA on T cell responses. 
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1. Hantavirus Cardiopulmonary Syndrome and Hemorrhagic Fever with Renal Syndrome 
Hantaviruses are RNA viruses possessing a segmented negative-stranded RNA genome belonging 
to the family Bunyaviridae, genus Hantavirus [1], and are conventionally divided into the Old World 
and the New World hantaviruses based on the geographic regions where they occur [2]. The Old 
World  hantaviruses,  including  Hantaan  virus  (HTNV),  Seoul  virus  (SEOV),  Dobrava  virus,  and 
Puumala viruses (PUUV), which are seen throughout Europe and Asia, cause a human disease known 
as hemorrhagic fever with renal syndrome (HFRS), which is clinically characterized by non-specific 
flu-like symptoms followed by thrombocytopenia, and a capillary leak syndrome with hemoconcentration. 
In severe cases renal failure and shock can develop [1,3]. Mortality rates vary from less than 1%  
to 15%, depending on the individual virus [1,2,4]. The New World hantaviruses include Sin Nombre 
virus (SNV) and Andes virus (ANDV) seen in the Americas [1,2,4], which were recognized as a cause 
of disease when the first outbreak of hantavirus cardiopulmonary syndrome (HCPS, it was initially 
named hantavirus pulmonary syndrome (HPS), which is still being widely used in literature) occurred 
in the southwestern United States in 1993 (a history of the discovery of the hantaviruses are described 
in  a  review  by  Hjelle  and  Torres-Pérez  in  this  special  issue  “Pathogenesis  of  Emerging  and  
Re-Emerging  RNA  Viruses”  [2]).  HCPS  shares  many  characteristics  with  HFRS,  including 
thrombocytopenia and a capillary leak syndrome except for its target organ. The pathology seen with 
Old  World  hantaviruses  focuses  on  the  kidney,  but  the  major  target  organ  for  the  New  World 
hantaviruses is the lung, although there are recent reports of PUUV infection which met the HCPS case 
definition [5] and renal sequelae observed in HCPS cases [6]. HCPS cases also progress to a severe 
degree more frequently than do HFRS cases. The latest mortality rate of HCPS in the US is 36% [7]. 
The  molecular  characteristics  of  hantaviruses,  and  clinical  and  pathological  descriptions  of  the 
HCPS and HFRS are also reviewed in this special issue [2].  
2. Involvement of T Cells in the Pathological Changes 
Pathological  changes  in  HCPS  and  HFRS  are  characterized  by  an  increased  permeability  in 
microvascular beds of affected organs, the kidney in HFRS and the lung in HCPS, and endothelial 
cells are considered to be the primary targets of hantavirus infection  [3,8–11]. In vitro hantavirus 
infection alone, however, did not induce visible cytopathic effects in cultured human endothelial cells 
[12–15]. Hantavirus infection also induced little or no increase in capillary permeability of an infected 
endothelial  cell  monolayer  [15–18].  Because  direct  effects  of  hantavirus  infection  on  endothelial 
functions were recently reviewed by Mackow and Gavrilovskaya [19], in this review we will focus on 
immune-mediated mechanisms of the HCPS and HFRS pathogenesis.  
There are observations suggesting immune-mediated mechanisms in the pathogenesis of the HCPS 
and HFRS (previously published reviews discussing immune mechanisms in hantavirus pathogenesis 
by us and others are [3,20–25]). (1) In HCPS, large immunoblasts were seen in the circulation at the 
onset of pulmonary edema and shock [26] and in necropsy lung tissues [10,27], and in HFRS T cell 
activation  in  the  acute  phase  was  also  reported  [28,29];  (2)  Although  the  levels  of  viremia  on 
admission correlated with disease severity in HCPS cases [30,31], viremia was cleared soon after the 
onset of lung edema, but the disease continued to progress [30]; (3) We showed the presence of high Viruses 2011, 3                         
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levels of cytokine producing cells in lung tissues from patients with fatal HCPS [32]. The cytokines 
detected include tumor necrosis factor (TNF)-α, interleukin (IL)-2, IL-6 and interferon (IFN)-γ, which 
are  produced  by  T  cells  and  may  mediate  capillary  leakage.  Exposure  to  high  doses  of  TNF-α  
in vivo is known to induce shock, capillary leakage, pulmonary edema, and mortality [33], and therapy 
with high doses of IL-2 causes an increase in vascular permeability [34,35]. Also in nephropathia 
epidemica (NE), a milder form of HFRS caused by PUUV, lymphocyte infiltration, predominantly of 
CD8
+  T  cells,  was  observed  in  the  kidney  accompanied  by  TNF-α  expression  [36],  and  elevated 
plasma levels of TNF-α, IL-6, and IL-10 were reported [37]; (4) Genetic linkage analysis, which will 
be described in the next section also suggest that the involvement of T cells, especially CD8
+ T cells, 
in the pathogenesis of the HCPS and HFRS; (5) An in vitro transwell permeability assay demonstrated 
that  SNV  infection  of  human  endothelial  cell  line  and  the  virus-specific  CD8
+  T  cells  increased 
permeability, but infection or CD8
+ T cells alone did not [18]. Autopsies performed on patients with 
fatal HCPS, however, demonstrated that infected lung endothelial cells were not necrotic and the lung 
architecture  appeared  to  be  grossly  intact  [10,27].  In  vivo  the  main  mechanism  for  increased 
permeability may be the release of cytokines, such as TNF-α, by the virus-specific CD8
+ T cells rather 
than direct lysis of endothelial cells. Interestingly HTNV, SEOV and Dobrava virus were found to 
inhibit TNF-α-induced nuclear factor κ B activation, but PUUV, SNV and ANDV were not [38,39]. 
Gavrilovskaya et al. reported that human pathogenic hantaviruses, such as HTNV, ANDV and New 
York-1 virus, did increase sensitivity of infected endothelial cells to vascular endothelial growth factor 
[40], which has permeabilizing effects on endothelium  [41]. In the in vitro transwell permeability 
assay we did not perform experiments identifying molecules mediating the increased permeability.  
We  previously  discussed  mouse  experiments  performed  in  the  context  of  transplant  rejection 
[42,43] in a brief review [25]. Transgenic mice which expressed β-galactosidase (BG) protein in the 
endothelial cells were used as a model. Infection of these transgenic mice with recombinant vaccinia 
virus expressing BG protein induced humoral and cellular immune responses against the BG protein 
(the BG protein was not tolerated!). The infected transgenic mice, however, remained healthy. No 
damage was observed in endothelial cells expressing BG protein, which were supposed to be a target 
of the humoral and cellular immune responses. The transgenic mice also remained healthy after primed 
spleen cells or lymph node cells from immunized wild type mice, which contained T cells reacting to 
BG  protein,  were  adoptively  transferred  into  them.  These  series  of  experiments  suggest  that  in 
laboratory mice (FVB background) endothelial cells are somehow protected from humoral and cellular 
immune responses, which is in contrast with transgenic mouse model of influenza virus infection, in 
which  adoptive  transfer  of  hemagglutinin-specific  CD8
+  T  cells  into  transgenic  mice  expressing 
hemagglutinin in lung alveolar epithelial cells induced lung injury [44,45]. Activated endothelial cells 
are  known  to  express  programmed  death  ligand-1  (PD-L1)  and  PD-L2,  which  can  down-regulate  
CD8
+ T cell activation and lysis [46–48]. In the transplant rejection model, the BG protein-specific 
CD8
+ T cells may have been inactivated by these molecules expressed on the endothelial cells, or there 
may not have been enough BG protein-specific CD8
+ T cells to overcome this protective mechanism. 
In HCPS and HFRS patients there may be an overwhelming amount of activated CD8
+ T cells, or  
the  protecting  mechanisms  may  not  be  functioning  properly  because  of  hantavirus  infection  of 
endothelial cells. Viruses 2011, 3                         
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Recently  Björkstrom  et  al.  reported  rapid  expansion  and  long-term  (>60  days)  persistence  of 
elevated NK cell numbers in HFRS patients, which may have relevance to immunopathogenesis [49]. 
3. Genetic Susceptibility to HCPS and HFRS 
MHC class I and class II molecules bind and present viral peptide fragments to CD8
+ and CD4
+ T 
cells. Different MHC class I and class II molecules present different sets of viral peptides; therefore, 
CD8
+ and CD4
+ T cell responses in individuals carrying different MHC class I and class II molecules, 
which are encoded by HLA-A, -B and -C genes (MHC class I molecules) and HLA-DR, -DP and -DQ 
genes,  (MHC  class  II  molecules),  may  be  different  [50].  In  NE  caused  by  PUUV  infection,  the  
HLA-B8-DR3 extended haplotype was associated with severe outcome of the disease [51,52] and with 
higher PCR positivity of the virus in clinical samples (reflecting prolonged or higher levels of viremia) 
[53], and HLA-B27 was associated with milder disease [54] in Finland. The B8-DRB1*03 haplotype 
was  also  significantly  higher  in  pediatric  NE  patients  [55].  In  the  Chinese  Han  population  the  
HLA-DRB1*09 was significantly higher in HFRS patients [56]. Interestingly, as Wang et al. pointed 
out [56], the B8-DR3 haplotype is common in the Finnish population, but rare in the Chinese Han 
population.  In  contrast,  the  DRB1*09  is  common  in  the  Chinese  Han  population,  but  rare  in  the 
Finnish population [57,58]. In HCPS caused by SNV in the southwestern US, the HLA-B*3501 allele 
was  associated  with  increased  risk  for  developing  severe  HCPS  [59,60],  while  HCPS  caused  by 
ANDV  in  Chile  the  HLA-B8  was  associated  with  severe  disease  and  the  HLA-DRB1*15  was 
associated with mild disease [61]. In this Chilean study, contrary to the study in the southwestern US, 
the HLA-B35 allele was found more frequently in patients with mild disease than in patients with 
severe disease.  
There is one report which clearly showed that the difference in the MHC class I molecule alone can 
influence disease outcome of viral infection [62]. Flatz et al. accidentally observed that humanized 
mice which express the human/mouse-chimeric HLA-A2.1 molecule instead of the murine MHC class 
I molecules (HHD mice) developed disease similar to severe Lassa fever (Lassa fever [63,64] is caused 
by a member of arenavirus family, Lassa virus, not by hantaviruses). The wild type C57BL/6 and the 
HHD mice had the same levels of viremia up to 4 days after infection, but by day 7 the wild type mice 
cleared the virus without any clinical evidence of disease, while the HHD mice were not able to clear 
the virus and some (22%) died. The HHD mice share the same genetic background with the C57BL/6 
mice except for the MHC class I; therefore, the results suggested that the wild type mouse’s MHC 
class I-restricted (i.e., H-2D
b and H-2K
b-restricted) CD8
+ T cell responses are important for controlling 
the  virus  infection  and  the  HHD  mouse’s  class  I-restricted  (HLA-A2.1-restricted)  CD8
+  T  cell 
responses cannot control the virus. 
4. Targets of T Cell Responses 
Hantaviruses have four proteins encoded by three genomic RNA segments. Nucleocapsid protein 
(N) is encoded by the S segment. Two envelope glycoproteins, Gn and Gc (formerly called G1 and 
G2),  are  proteolytically  processed  from  the  glycoprotein  precursor  encoded  by  the  M  segment.  
RNA-dependent RNA polymerase (L) is encoded by the L segment [11] In humans CD4
+ and CD8 T
+ 
cell epitopes on hantavirus proteins were identified by analyzing peripheral blood mononuclear cells Viruses 2011, 3                         
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(PBMCs) obtained either from donors who had immune memory to the virus [65–69] or from HCPS or 
HFRS patients in the acute phase [60,70–72]. Well-characterized epitopes (minimal epitopes and HLA 
restrictions have been determined, and specific T cells have been detected in or specific T cell lines 
have been generated from human PBMCs) are listed in Table 1. In HCPS caused by SNV and ANDV, 
very high frequency of single epitope-specific CD8 T cells were reported by MHC/peptide tetramer 
staining (G664-673 and G746-755 for SNV and G465-473 for ANDV) [60,69]. These epitopes are on the 
envelope glycoproteins. In contrast, in HFRS most epitopes identified to date are on the N of Hantaan 
virues  (HTNV)  and  PUUV.  PBMCs  from  some  of  HTNV-  and  PUUV-immune  donors  showed 
cytotoxicity against the Gn or Gc after in vitro stimulation by the virus, although N were recognized 
more frequently than Gn or Gc [65,67]. These studies were very limited. Except for one study testing a 
small number of peptides identified by an MHC class I binding motif search on the L [71], none of 
these studies tried to detect T cell responses to L or to identify T cell epitopes on the L protein.  
Studies  analyzing  donors  who  had  experienced  HCPS  or  HFRS  years  ago  showed  that  T  cell 
memory is long-lived [65–67,69], although one report implied the possibility of persistent presence of 
ANDV antigen after acute infection [69].  
Table 1. CD8
+ T cell epitopes identified in hantavirus proteins 
a. 
Epitope  Amino Acid Sequence  Virus  HLA Restriction  Reference 
N131-139  LPIILKALY  Sin Nombre  B*3501  [70] 
N234-242  ERIDDFLAA  Sin Nombre  Cw7  [70] 
G664-673
b  TAHGVGIIPM  Sin Nombre  B*3501  [60] 
G746-755
b  YPWQTAKCFF  Sin Nombre  B*3501  [60] 
G465-473
c  LMPDVAHSL  Andes  B*3501  [69] 
N12-20  NAHEGQLVI  Hantaan  B51  [65] 
N421-429  ISNQEPLKL  Hantaan  A1  [65] 
N334-342  ILQDMRNTI  Hantaan  A2.1  [71] 
L512-520  ILPSKSLEV  Hantaan  A2.1  [71] 
L1273-1281  IMELATAGI  Hantaan  A2.1  [71] 
L1736-1744  GLDCARLEI  Hantaan  A2.1  [71] 
N173-181  RPKHLYVSM  Puumala  B7/B8
d  [67] 
N204-212  GLFPTQIQV  Puumala  A2.1  [67] 
N243-51  ECOFIKPEV  Puumala  B8  [67] 
G731-939
b  HWMDATFNL  Puumala  A24  [66] 
a For all epitopes listed, minimal epitopes and HLA restrictions have been determined, and specific 
T cells have been detected in or specific T cell lines have been generated from human PBMCs;  
b Amino acid numbering is based on the sequence of glycoprotein precursor. These epitopes are 
located on the Gc; 
c Amino acid numbering is based on the sequence of glycoprotein precursor. 
This epitope is located on the Gn; 
d Restricted by both HLA-B7 and B8 molecules. 
5. Disease Severity and T Cell Responses—Published Clinical Studies 
By analyzing PBMC samples obtained from HCPS patients with MHC/peptide tetramer staining we 
showed that there were high frequencies of SNV epitope-specific CD8
+ T cells in the acute phase [60] 
compared  to  the  frequencies  of  epitope-specific  CD8
+  T  cells  in  the  acute  phases  of  other  viral Viruses 2011, 3                         
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infections, such as human immunodeficiency virus, hepatitis C virus, hepatitis B virus, vaccinia virus 
and dengue virus, quantitated by MHC/peptide tetramer staining, in which the frequencies were often 
<1% [73–81]. Acute infectious mononucleosis by Epstein-Barr virus is the only other human viral 
infection with comparable frequencies of epitope-specific CD8
+ T cells [82–85]. We also found that 
the frequencies were significantly higher in eight patients with severe HCPS requiring mechanical 
ventilation  (16.5  ±  5.9%  (average  ±  standard  deviation)  of  CD8
+  T  cells  at  earliest  time  points,  
18.3  ±  6.6%  at  peak  responses)  than  in  three  moderately  ill  HCPS  patients  hospitalized  but  not 
requiring mechanical ventilation (5.9 ± 3.5% of CD8
+ T cells at earliest time points, 6.6 ± 2.8% at peak 
responses) (in the original paper [60], we used the Wilcoxon rank sum test to compare the severe and 
the moderate cases, and found statistically significant differences both at earliest time points and peak 
responses), suggesting immunopathological roles of these SNV-specific CD8
+ T cells.  
In HFRS, contrary to the finding in HCPS, Wang et al. reported that frequencies of HTNV-specific 
cells, which were quantitated by ELISPOT assays using overlapping peptides covering the N protein of 
HTNV, were significantly higher in patients with mild or moderate HFRS than in those with severe or 
critical HFRS, suggesting protective roles of these HTNV-specific cells [86].  
There are several critical methodological differences between these two studies. The HCPS study 
[60] used HLA-B*3501/peptide tetramers to detect SNV-specific T cells, which enabled us to analyze 
only patients carrying the HLA-B*3501 allele (risk factor for severe HCPS and relatively common 
allele among HCPS patients [59]). The tetramers detected CD8
+ T cells specific to three epitopes  
(N131-139, G664-673 and G746-755 in Table 1) irrespective of these T cells’ function. CD8
+ T cells specific 
to other epitopes could not be analyzed by these tetramer staining. The HFRS study [86] used IFN-γ 
ELISPOT assays to detect HTNV-specific T cells. PBMCs were stimulated with pools of peptides 
covering the entire N protein to produce IFN-γ, meaning that only T cells which were specific to the N 
protein and were able to secrete IFN-γ were detected. 
In  the  study  analyzing  CD8  T  cell  memory  generation  in  NE  patients  caused  by  PUUV  
Tuuminen  et  al.  found  huge  difference  between  frequencies  of  PUUV  N204-212-specific  T  cells 
quantitated  by  HLA-A2/N204-212  tetramer  staining  and  by  IFN-γ  ELISPOT  assays  with  the  same 
peptide in the PBMC obtained in the acute phase of the disease (3200 ~ 19800 N204-212-specific cells 
per  million  PBMCs  by  the  tetramer  staining  and  <50  ~  300  by  IFN-γ  ELISPOT  assays  at  the 
presentation to hospital) and during the follow-up the difference became much smaller [87]. Therefore, 
by  the  tetramer  staining  PUUV-specific  T  cells  showed  expansion  and  contraction,  but  by  IFN-γ 
ELISPOT assays PUUV-specific T cells showed a gradual increase. By the ex vivo analysis combining 
the tetramer staining and intracellular cytokine staining the authors found that on average 15.2% of 
tetramer-positive  cells  in  the  acute  phase  and  5.1%  in  the  convalescent  phase  expressed  IFN-γ, 
suggesting that the IFN-γ ELISPOT assays underestimated the frequency of PUUV N204-212-specific T 
cells in the acute phase samples. They also showed that cells isolated during the acute phase were more 
prone to activation-induced apoptosis than cells isolated during convalescence, which may account for 
the  difference  which  cannot  be  explained  by  the  low  percentage  of  IFN-γ-producing  cells  in  the 
tetramer  positive  population  in  the  acute  phase.  A  similar  scenario  may  have  happened  to  
HTNV-specific T cells in the HFRS study, in which the numbers of HTNV-specific T cells (specific to 
the N protein) in the acute phase quantitated by IFN-γ ELISPOT assays were in the range of hundreds, 
not in the thousands [86]. Quantitating HTNV-specific T cells by tetramer staining is likely to clarify if Viruses 2011, 3                         
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there is early expansion of the specific T cells in the acute phase of HFRS and if there is correlation 
between  the  disease  severity  and  the  frequencies  of  the  specific  T  cells.  It  is  also  important  to 
quantitate T cells specific to epitopes restricted by other alleles (so far only B*3501/peptide tetramers 
[60,69] and HLA-A2/peptide tetramers [87] have been used for quantitation).  
6. Syrian Golden Hamster Model of HCPS 
During vaccine studies, ANDV, but not SNV, was found to cause disease very similar to HCPS in 
Syrian golden hamsters [88,89]. Both viruses infect Syrian golden hamsters, but only ANDV causes 
viremia  [90].  Two  New  World  hantaviruses  which  are  not  known  to  cause  diseases  in  humans, 
Maporal virus and Choclo virus, were also tested in Syrian golden hamsters [91,92]. While Maporal 
virus caused a disease pathologically similar to the HCPS-like disease caused by ANDV [91], Choclo 
virus did not cause any symptoms of the disease. When compared to animals infected with ANDV, the 
prevalence of antigen-positive  endothelial cells in  the  lungs  of Choclo virus-infected  animals  was 
similar, but no inflammatory cellular infiltrate or lung edema were observed [92], suggesting that host 
immune responses are necessary for Syrian golden hamsters to develop the HCPS-like disease. 
7. Regulatory T Cells in Hantavirus Infection 
The  natural  reservoir  of  hantaviruses  are  persistently  infected  rodents  [93].  There  are  many 
mechanisms proposed to explain viral persistence and the relative absence of disease in these rodent 
reservoirs (reviewed in [93,94]). One of them is suppression of proinflamatory and effector T cell 
activity by regulatory T cells [95,96]. 
Seoul virus, which causes HFRS, is maintained in Norway rats. Easterbrook et al. hypothesized that 
Seoul virus may exploit regulatory T cell responses to cause persistence in rats [97]. To test their 
hypothesis, regulatory T cells were inactivated by injecting anti-CD25 monoclonal antibody into rats 
inoculated with Seoul virus (Seoul virus infection increases CD4
+CD25
+FoxP3
+ regulatory T cells in 
these rats). Consistent with the hypothesis, inactivation of regulatory T cells reduced the amount of 
Seoul virus RNA in the lung (target organ of the Seoul virus infection in rats) and saliva. Absence of 
regulatory T cells may result in uncontrolled effector T cell activity and causes tissue damage through 
immunopathological  mechanisms.  In  this  experimental  setting,  however,  the  average  amount  of 
hemorrhage and edema in the lung was not increased in rats whose regulatory T cells were inactivated 
by the anti-CD25 antibody injection [97]. There is a possibility that, because activated T cells also 
express CD25, anti-CD25 antibody treatment may have inactivated activated effector T cells as well as 
regulatory T cells and prevented immunopathology. The authors think it unlikely because during acute 
and persistent Seoul virus infection >90% of CD4
+CD25
+ T cells were FoxP3
+ regulatory T cells. 
Abel Borges and Figueiredo speculated that active suppression of immune T regulatory cells is 
probably involved in HCPS pathogenesis [98]. Zhu et al. analyzed regulatory T cells in patients with 
HFRS [99]. They found that, in contrast to Norway rats infected with Seoul virus [97], the frequency 
of regulatory T cells identified as CD4
+CD
25high was reduced in the acute phase of HFRS compared to 
the  convalescent  phase  and  levels  in  healthy  controls.  In  these  HFRS  patients  the  frequencies  of 
regulatory T cells inversely correlated with disease severity, suggesting that inefficient control of T 
cell effecter functions may be responsible for more severe disease, although HNTV-specific T cells Viruses 2011, 3                         
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were  not  directly  analyzed  in  this  study  and  identifying  regulatory  T  cells  by  CD4  and  CD25 
expression alone in humans may be controversial [100]. It should also be noted that in Norway rats 
Seoul virus causes persistent infection, not acute infection similar to HFRS. 
8. Immunopathological Mechanisms 
Numerous studies of influenza virus infection (reviewed in [101]) suggest that almost all mediators 
of pathological changes are also essential for efficient viral clearance, which is likely to be true to 
hantavirus infection. There are two possible scenarios of immunopathological mechanisms for HCPS 
and HFRS. (1) T cell responses eliminate virus, but intensive T cell responses may alter endothelial 
cell function (capillary leakage) by secreting an excessive amount of cytokines. (2) Conversely, if 
sufficient amount of T cell responses is not induced, virus clearance is delayed leading to prolonged 
inflammation,  which  may  also  alter  endothelial  cell  function  by  non-T  cell-mediated  mechanisms  
(e.g.,  as  mentioned  earlier,  human  pathogenic  hantaviruses  can  increase  sensitivity  of  infected 
endothelial cells to vascular endothelial growth factor [40]). The HCPS clinical study, in which the 
frequencies of the virus-specific T cells correlated with disease severity [60], and the HFRS clinical 
study by Zhu et al., in which decreases in the numbers of regulatory T cells (presumably meaning 
increases in effector CD8
+ T cell responses) correlated with disease severity [99], correspond to the 
first scenario that intensive T cell responses cause the HCPS and HFRS. The other HFRS clinical study 
by Wang et al. reporting that frequencies of virus-specific T cells inversely correlate with disease 
severity [86] corresponds to the second scenario.  
9. Conclusions 
In both HCPS and HFRS, CD8
+ T cell responses are essential for elimination of virus-infected cells 
and viral clearance. Both too strong and too weak T cell responses may lead to severe disease. It is 
important to clarify the role of T cells in these diseases for better treatment (whether to suppress T cell 
functions) and protection (vaccine design) which may need to take into account viral factors and the 
influence of HLA on T cell responses. 
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